The new company aims to combine with a life sciences target with innovative biotech, pharmaceutical or diagnostics technology. BCLS is led by Chairman Adam Koppel, CEO and Director Jeffrey Schwartz and CFO and Director Andrew Hack.
Total SPAC deal count for 2020 year-to-date is now 157 with $58.4 billion in gross proceeds raised. This offering is expected to close on Monday, October 26.
Goldman Sachs & Co. LLC and Jefferies LLC are serving as joint book-running managers for the offering. Kirkland & Ellis LLP and Maples and Calder are serving as Issuer’s Counsel with Ropes & Gray LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company LLC is acting as trustee.